OpenAI’s Sam Altman and Science VP Kevin Weil Promote AI-Driven Dog Cancer Story Despite Lack of Vaccine Evidence

On March 29, 2026, OpenAI’s CEO Sam Altman and VP Kevin Weil highlighted a story of an Australian AI consultant, Paul Conyngham, who used ChatGPT and AlphaFold to develop a personalized mRNA vaccine for his dog Rosie, diagnosed with terminal cancer. Altman described the meeting as the “coolest” of the week, emphasizing AI’s role in advancing personalized medicine, with Weil stating it offers a “glimpse of the future.” However, critics like Egan Peltan argue there’s no evidence that the vaccine had any efficacy or safety, given Rosie was also on an FDA-approved PD-1 immunotherapy, which could explain her cancer’s improvement. Peltan views the narrative as a venture-driven exaggeration and stresses the importance of rigorous clinical trials and evidence before promoting new therapies. He points out the high costs associated with such treatments and the long path to regulatory approval, highlighting that AI’s role in such medical advancements shouldn’t be overstated.

Source link